Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug893 | Chat-based instant messaging support Wiki | 1.00 |
| drug3560 | Self-help booklet Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This pilot trial aims to evaluate the effectiveness of chat-based instant messaging support in preventing smoking relapse in recent tobacco abstainers.
Description: Defined by an exhaled carbon monoxide level of 3 parts per million or below
Measure: Biochemically-validated tobacco abstinence Time: Assessed at 6 months after randomisationDescription: Not more than five lapses permitted for 6 months after baseline
Measure: Self-reported 6-month prolonged tobacco abstinence Time: Assessed at 6 months after randomisationDescription: Being completely smoke-free in the past 7 days
Measure: Self-reported 7-day point-prevalence tobacco abstinence Time: Assessed at 3 months after randomisationDescription: Being completely smoke-free in the past 7 days
Measure: Self-reported 7-day point-prevalence tobacco abstinence Time: Assessed at 6 months after randomisationDescription: Defined as use of tobacco products for 7 consecutive days or longer
Measure: Self-reported relapse rate Time: Assessed at 3 months after randomisationDescription: Defined as use of tobacco products for 7 consecutive days or longer
Measure: Self-reported relapse rate Time: Assessed at 6 months after randomisationDescription: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.
Measure: Change in self-efficacy to quit smoking Time: Assessed at 3 months after randomisationDescription: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.
Measure: Change in self-efficacy to quit smoking Time: Assessed at 6 months after randomisationDescription: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.
Measure: Nicotine withdrawal Time: Assessed at 3 months after randomisationDescription: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.
Measure: Nicotine withdrawal Time: Assessed at 6 months after randomisationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports